The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth
Abstract
E7389, which is in phase I and II clinical trials, is a synthetic macrocyclic ketone analogue of the marine sponge natural product halichondrin B. Whereas its mechanism of action has not been fully elucidated, its main target seems to be tubulin and/or the microtubules responsible for the construction and proper function of the mitotic spindle. Like most microtubule-targeted antitumor drugs, it inhibits tumor cell proliferation in association with G2-M arrest. It binds to tubulin and inhibits microtubule polymerization. We examined the mechanism of action of E7389 with purified microtubules and in living cells and found that, unlike antimitotic drugs including vinblastine and paclitaxel that suppress both the shortening and growth phases of microtubule dynamic instability, E7389 seems to work by an end-poisoning mechanism that results predominantly in inhibition of microtubule growth, but not shortening, in association with sequestration of tubulin into aggregates. In living MCF7 cells at the concentration that half-maximally blocked cell proliferation and mitosis (1 nmol/L), E7389 did not affect the shortening events of microtubule dynamic instability nor the catastrophe or rescue frequencies, but it significantly suppressed the rate and extent of microtubule growth. Vinblastine, but not E7389, inhibited the dilution-induced microtubule disassembly rate. The results suggest that, at its lowest effective concentrations, E7389 may suppress mitosis by directly binding to microtubule ends as unliganded E7389 or by competition of E7389-induced tubulin aggregates with unliganded soluble tubulin for addition to growing microtubule ends. The result is formation of abnormal mitotic spindles that cannot pass the metaphase/anaphase checkpoint.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Self-citationDynamic instability of microtubule growth
Mitchison, T., & Kirschner, M. (1984) · Nature · doi:10.1038/312237a0 · Cited by 3,337
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.
Jordan, M. A., Toso, R. J., Thrower, D., & Wilson, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9552 · Cited by 1,095
Self-citationWalker, R. A., O'Brien, E. T., Pryer, N. K., Soboeiro, M. F., Voter, W. A., Erickson, H. P., & Salmon, E. D. (1988) · The Journal of Cell Biology · doi:10.1083/jcb.107.4.1437 · Cited by 980
Mechanism of Action of Antitumor Drugs that Interact with Microtubules and Tubulin
Jordan, M. (2012) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011023354290 · Cited by 775
Self-citationJordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., & Wilson, L. (1996) · PubMed · Cited by 770
Self-citationRieder, C. L., Cole, R. W., Khodjakov, A., & Sluder, G. (1995) · The Journal of cell biology · doi:10.1083/jcb.130.4.941 · Cited by 713
Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together
Wang, T.-H., Wang, H.-S., & Soong, Y.-K. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2619::aid-cncr26>3.0.co;2-j · Cited by 647
Taxol Suppresses Dynamics of Individual Microtubules in Living Human Tumor Cells
Yvon, A.-M. C., Wadsworth, P., & Jordan, M. A. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.4.947 · Cited by 553
Self-citation
Cited by
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
The odyssey of marine pharmaceuticals: a current pipeline perspective
Mayer, A. M. S., Glaser, K. B., Cuevas, C., Jacobs, R. S., Kem, W., Little, R. D., McIntosh, J. M., Newman, D. J., Potts, B. C., & Shuster, D. E. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.02.005 · Cited by 666
Drug discovery from natural sources
Chin, Y.-W., Balunas, M. J., Chai, H. B., & Kinghorn, A. D. (2006) · The AAPS Journal · doi:10.1007/bf02854894 · Cited by 662
Perez, E. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0366 · Cited by 521
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Metadata
- Authors
- Jordan, M. A., Kamath, K., Manna, T., Okouneva, T., Miller, H. P., Davis, C., Littlefield, B. A., & Wilson, L.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2005-07-01
- Volume
- 4
- Issue
- 7
- Pages
- 1086-1095
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2123851255
- Cited by
- 489
- References
- 44
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. https://app.cochat.ai/papers/10.1158/1535-7163.mct-04-0345
- The paper
- Jordan, M. A., Kamath, K., Manna, T., Okouneva, T., Miller, H. P., Davis, C., Littlefield, B. A., & Wilson, L. (2005). The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-04-0345
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.